Key result
The CHA2DS2-VASc and CHA2DS2-VASc-HS scores did not predict in-stent restenosis among 358 patients (42 with ISR, 316 without) after coronary drug-eluting stent placement.
Why the study?
The ability of the CHA2DS2-VASc and CHA2DS2-VASc-HS scoring systems to predict in-stent restenosis among patients undergoing drug-eluting stent implantation had not been established.
Do the CHA2DS2-VASc and CHA2DS2-VASc-HS scores predict in-stent restenosis in patients undergoing coronary drug-eluting stent implantation?
Cohort (n=358)
Do the CHA2DS2-VASc and CHA2DS2-VASc-HS scores predict in-stent restenosis in patients undergoing coronary drug-eluting stent implantation?
The CHA2DS2-VASc and CHA2DS2-VASc-HS scores are not effective predictors of in-stent restenosis following coronary drug-eluting stent implantation.
CHA2DS2-VASc scores do not predict post-DES ISR; should not yet inform practice and leaves open validation in prospective cohorts.
Objective To evaluate the ability of two scoring systems (CHA 2 DS 2 -VASc score and CHA 2 DS 2 -VASc+hyperlipidaemia+smoking [CHA 2 DS 2 -VASc-HS score]) to predict in-stent restenosis (ISR) among patients undergoing drug-eluting stent (DES) implantation. Methods This retrospective study enrolled patients who underwent coronary angiography to assess coronary artery disease severity secondary to a diagnosis of stable angina or acute coronary syndrome that subsequently underwent DES implantations. Demographic, clinical, angiographic and biochemical parameters were compared between those patients that experienced ISR and those that did not during the study follow-up period. Univariate and multivariate logistic regression analyses were used to evaluate associations between the baseline parameters, the two scoring systems and ISR risk. Results A total of 358 patients (non-ISR group n = 316; ISR group n = 42) participated in the study. Compared with the non-ISR group, more patients in the ISR group had diabetes mellitus and received stents with smaller diameters but longer lengths. There were no significant differences with regard the predictive ability for ISR of either the CHA 2 DS 2 -Vasc or the CHA 2 DS 2 -Vasc-HS scores. Multivariate logistic regression analyses demonstrated that stent diameter, follow-up duration and glycosylated haemoglobin were independent risk factors for ISR. Conclusions The CHA 2 DS 2 -Vasc and CHA 2 DS 2 -Vasc-HS scores did not predict ISR in patients after coronary DES placement.
No takes yet. Share an insight, caveat, or question.
Zhao et al. (2019) conducted a cohort in Coronary artery disease with DES implantation (n=358). CHA2DS2-VASc and CHA2DS2-VASc-HS scores was evaluated on In-stent restenosis (ISR). The CHA2DS2-VASc and CHA2DS2-VASc-HS scores did not predict in-stent restenosis among 358 patients (42 with ISR, 316 without) after coronary drug-eluting stent placement.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: